Allos Therapeutics, Inc.
11080 CirclePoint Road
Suite 200
Westminster
Colorado
80020
United States
Tel: 303-426-6262
Fax: 303-426-4731
Website: http://www.allos.com/
Email: corpcomm@allos.com
210 articles about Allos Therapeutics, Inc.
-
Allos Therapeutics, Inc. Reports Second Quarter 2010 Financial Results
7/28/2010
-
Allos Therapeutics, Inc. Announces Topline Results from Phase 2b Study of FOLOTYN in Patients with Advanced Non-Small Cell Lung Cancer
7/28/2010
-
Allos Therapeutics, Inc. to Report Second Quarter 2010 Financial Results on July 28, 2010
7/12/2010
-
Allos Therapeutics, Inc.' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Cutaneous T-Cell Lymphoma by the European Commission
6/17/2010
-
Allos Therapeutics, Inc.'s FOLOTYN Shows Activity and Tolerability in Phase 1 Dose Finding Study in Patients with Relapsed or Refractory CTCL
6/11/2010
-
Allos Therapeutics, Inc. Reports New Data Demonstrating that Responses to FOLOTYN are Correlated with Prolonged Survival in Patients with Relapsed or Refractory PTCL
6/7/2010
-
Allos Therapeutics, Inc. to Present at Four Upcoming Investor Conferences
6/4/2010
-
Allos Therapeutics, Inc. to Present at the Citi Investment Research Global Health Care Conference
5/20/2010
-
Allos Therapeutics, Inc.'s Pralatrexate Granted FDA Orphan Drug Designation for the Treatment of Bladder Cancer
5/18/2010
-
Allos Therapeutics, Inc. Reports First Quarter 2010 Financial Results
5/6/2010
-
Allos Therapeutics, Inc. Appoints Dr. Charles Morris as Chief Medical Officer
4/27/2010
-
Allos Therapeutics, Inc. to Report First Quarter 2010 Financial Results on May 5, 2010
4/21/2010
-
Allos Therapeutics, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
3/2/2010
-
Allos Therapeutics, Inc. to Participate in RBC Capital Markets Health Care Conference
2/24/2010
-
Allos Therapeutics, Inc. to Report Fourth Quarter and Full Year 2009 Results on March 1, 2010
2/17/2010
-
Allos Therapeutics, Inc. to Present at Biotechnology Industry Organization (BIO) CEO & Investor Conference
2/3/2010
-
Allos Therapeutics, Inc. to Present at J.P. Morgan Healthcare Conference
1/6/2010
-
Allos Therapeutics, Inc.'s FOLOTYN(TM) Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
12/8/2009
-
Allos Therapeutics, Inc.' FOLOTYN(TM) Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Treated with Stem Cell Transplant
12/7/2009
-
Allos Therapeutics, Inc. Announces an Agreement with IDIS for a Named Patient Program for FOLOTYN(TM) (pralatrexate injection)
12/4/2009